Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819773) titled 'Device for Treating Generalized Anxiety' on Sept. 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).

Primary Sponsor: BTL Industries Ltd.

Condition: Generalized Anxiety Disorder (GAD)

Intervention: Device: EXOMIND (BTL-699-2) Active treatment

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: September 9, 2026

Target Sample Size: 40

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07819773

Published by HT Digital Content ...